Service Innovation - UHS Pharmacy an Opportunity to Increase the Coverage of ...Health Innovation Wessex
Getting To Grips with Alcohol 2016
Presentation Slides
Service Innovation - UHS Pharmacy an opportunity to increase the coverage of identification and brief advice
Jacqueline Swabe and Lindsay Steel
Service Innovation - UHS Pharmacy an Opportunity to Increase the Coverage of ...Health Innovation Wessex
Getting To Grips with Alcohol 2016
Presentation Slides
Service Innovation - UHS Pharmacy an opportunity to increase the coverage of identification and brief advice
Jacqueline Swabe and Lindsay Steel
Service Innovation - HSJ Finalist; Setting up Poole Alcohol Care and Treatmen...Health Innovation Wessex
Getting to Grips with Alcohol 2016
Presentation Slides
Service Innovation - HSJ Finalist
Setting up the Poole Alcohol Care & Treatment Services
Graeme White
Developing and implementing clinical standards for seven day servicesNHS Improving Quality
Celia Ingham Clark National Director: Reducing Premature Mortality. Slides from Celia's presentation from the 7 Day Services events West Midlands 11th June and East Midlands 12th June 2014
Presentation Overview
• Introduction to self-harm
• Hospital-treated self-harm in Ireland
• Treatment of self-harm
• Challenges and recommendations
• Actions from the Registry
Dr. Kathleen Brady of the AIDS Activities Coordinating Office presented this epidemiologic update to the Philadelphia EMA HIV Integrated Planning Council on February 9, 2018.
Aiming for a Higher Performing Health Care System: Learning from Cross-Nation...The Commonwealth Fund
Robin Osborn, Vice President and Director, International Program in Health Policy and Innovation at The Commonwealth Fund, discusses international health care systems. These slides were presented at the Queen’s Health Policy Change Conference, May 6, 2015 in Toronto, Canada.
Case studies and practical experience - alcohol problems in the workplaceiCAADEvents
Presentation given at iCAAD Sweden February 2018 by Frederick Sparring MD, Specialist in occupation medecin, MRO responsible for alcohol and drug rehabilitation at Avonova
Dr Samantha Smith delivered this presentation at an ESRI conference tilted ‘Health and social care supply and resource allocation planning in Ireland' on 24 September 2019.
There were two reports launched at the event. They can be read here:
‘An analysis of the effects on Irish hospital care of the supply of care inside and outside the hospital’
https://www.esri.ie/publications/an-analysis-of-the-effects-on-irish-hospital-care-of-the-supply-of-care-inside-and
‘Geographic profile of healthcare needs and non-acute healthcare supply in Ireland’
https://www.esri.ie/publications/geographic-profile-of-healthcare-needs-and-non-acute-healthcare-supply-in-ireland
Photos from the conference are available to view on the ESRI website here: https://www.esri.ie/events/health-and-social-care-supply-and-resource-allocation-planning-in-ireland
Drink Informed; Resources for Staff and Patients about the Health Harms of A...Health Innovation Wessex
Getting to Grips with Alcohol 2016
Presentation Slides
Drink Informed; Resources for staff and patients about the health harns of school
Elizabeth Raby
Service Innovation - HSJ Finalist; Setting up Poole Alcohol Care and Treatmen...Health Innovation Wessex
Getting to Grips with Alcohol 2016
Presentation Slides
Service Innovation - HSJ Finalist
Setting up the Poole Alcohol Care & Treatment Services
Graeme White
Developing and implementing clinical standards for seven day servicesNHS Improving Quality
Celia Ingham Clark National Director: Reducing Premature Mortality. Slides from Celia's presentation from the 7 Day Services events West Midlands 11th June and East Midlands 12th June 2014
Presentation Overview
• Introduction to self-harm
• Hospital-treated self-harm in Ireland
• Treatment of self-harm
• Challenges and recommendations
• Actions from the Registry
Dr. Kathleen Brady of the AIDS Activities Coordinating Office presented this epidemiologic update to the Philadelphia EMA HIV Integrated Planning Council on February 9, 2018.
Aiming for a Higher Performing Health Care System: Learning from Cross-Nation...The Commonwealth Fund
Robin Osborn, Vice President and Director, International Program in Health Policy and Innovation at The Commonwealth Fund, discusses international health care systems. These slides were presented at the Queen’s Health Policy Change Conference, May 6, 2015 in Toronto, Canada.
Case studies and practical experience - alcohol problems in the workplaceiCAADEvents
Presentation given at iCAAD Sweden February 2018 by Frederick Sparring MD, Specialist in occupation medecin, MRO responsible for alcohol and drug rehabilitation at Avonova
Dr Samantha Smith delivered this presentation at an ESRI conference tilted ‘Health and social care supply and resource allocation planning in Ireland' on 24 September 2019.
There were two reports launched at the event. They can be read here:
‘An analysis of the effects on Irish hospital care of the supply of care inside and outside the hospital’
https://www.esri.ie/publications/an-analysis-of-the-effects-on-irish-hospital-care-of-the-supply-of-care-inside-and
‘Geographic profile of healthcare needs and non-acute healthcare supply in Ireland’
https://www.esri.ie/publications/geographic-profile-of-healthcare-needs-and-non-acute-healthcare-supply-in-ireland
Photos from the conference are available to view on the ESRI website here: https://www.esri.ie/events/health-and-social-care-supply-and-resource-allocation-planning-in-ireland
Drink Informed; Resources for Staff and Patients about the Health Harms of A...Health Innovation Wessex
Getting to Grips with Alcohol 2016
Presentation Slides
Drink Informed; Resources for staff and patients about the health harns of school
Elizabeth Raby
İnovatif Kimya Dergisi Sayı-30 Anlatılan Konu Başlıkları
Doğal Polimerik Bambu
Atık Plastikten Geri Dönüşüm
Enstrumental Analiz ve Ötesi
John Dalton ve Hayat Hikayesi
Kimya Sektörü ve Sertifikalar
Ayın Web Sitesi, Kimya Sektöründen Haberler, Kimya Sözlüğü, Kimya Bulmacası ile Argon Elementi
İyi okumalar dileriz.
İnovatif Kimya Dergisi Sayı-10 Anlatılan Konu Başlıkları
Süt
Taş
Bitkiler Dünyamızı Temizliyor
Ozon Tabakası
Kaya (Şeyl) Gazı
Excel ve Kimya
Ayrıca Her Ay 3 Web Sitesi ve Kimya Bulmacası, Kimya Sektöründen Haberler ile Kimya Sözlüğü
İyi okumalar dileriz.
İnovatif Kimya Dergisi Sayı-9 Anlatılan Konu Başlıkları
Kimyanın Tarihsel Gelişimi
Kauçuk Derneği
Geleceğimizin Enerji Kaynağı-Bor
Polyester Mamüllerde Oligomer Sorunu
Matlab ve Kimya
Ayrıca Her Ay 3 Web Sitesi ve Kimya Bulmacası
İyi okumalar dileriz.
Microsoft dynamic GB slids
Microsoft Dynamics GP helps businesses gain greater control over their financials, better manage their inventory and operations, and make informed decisions that help drive business success. It's quick to implement and easy to use, with the power to support your growth ambition.
The third presentation delivered at the 'Big Data in health and care: using data to gain new insights’ event, hosted by Wessex Academic Health Science Network (AHSN) on 19 April 2015.
(EOR/MEOR/BERO)Application of bero™ biosurfactant in oklahoma and its effectJany Li
Within 6 months upon injection, the oil production of 21 production wells within the area of action greatly increased, wherein, the crude oil production of 16 oil wells increased by 2.8 times and that of the rest oil wells increased by 1.7 times on average. The oil recovery rate of this block was improved by 69%.
Audit of Inclusion Health in the Emergency Department.
Audit of the emergency care for the homeless population at City and Sandwell Hospitals, Birmingham.
Pathology Optimisation in Chronic Blood Disease MonitoringAndrew O'Hara
Richard Croker shows how an innovative approach to service redesign can improve patient outcomes at pace and scale through the safe and effective use of testing at NHS Northern, Eastern and Western Devon CCG.
Evidence shows us that specialised mood disorder clinics deliver cost savings, better clinical outcomes and improved patient satisfaction. Presented to the Trent Division of the Royal College of Psychiatrists, November 2013, Sheffield.
Revolutionizing Renal Care With Predictive Analytics for CKDViewics
Chronic Kidney Disease (CKD) is a common and growing condition, affecting about half of the Medicare population and of diabetics. In the United States, the lifetime risk of CKD for 30-year-olds is now greater than half, and the prevalence of CKD is projected to rise significantly over the next 15 years.
Current methods of predicting which CKD patients will progress to renal failure and require dialysis or transplant have low accuracy rates, causing great anxiety and suboptimal care. Without accurate risk prediction, many patients are over-treated, effectively wasting limited resources and negatively impacting outcomes. Conversely, other patients may receive inadequate treatment, restricting options to only the most costly and least desirable interventions.
Watch this on-demand webinar with Dr. Navdeep Tangri, developer of the Kidney Failure Risk Equation, which revolutionizes the way CKD patients are managed by leveraging laboratory data to accurately predict the risk of kidney failure in patients with CKD.
You’ll learn:
• How CKD is burdening our healthcare system, and the need for better care management tools
• How the Kidney Failure Risk Equation was researched, developed, and validated
• How Viewics is implementing CKD predictive analytics to automatically deliver risk information to clinicians and issue customized, educational reports to patients and clinicians
Julie Henderson (Acting Head of Clinical Services) discusses the Clinical Audit Service:
- Clinical Leadership and Engagement
- Inclusive Approach
- Audit Measurement
This presentation includes two case studies:
1) National Diabetes Audit
2) National Lung Cancer Audit
Centre for Mental Health and Wellbeing Research: Alcohol-related violence: What works and what do we need to do?A/Prof Peter Miller
University Consortium:
1School of Psychology, Deakin University
2National Addiction Centre, Institute of Psychiatry, King's College London, UK
3NDRI, Curtin University
4Commissioning Editor, Addiction
5Centre for Addiction and Mental Health, Ontario, Canada
Funded by the National Drug Law Enforcement Research Fund:An Initiative of the National Drug Strategy
Presented at the Australian Winter School
Research studies outcome of four studies regarding alcohol related violence.
TYA and Adult Late Effects Service at UCLHUCLPartners
Presentation by Victoria Grandage of University College London Hospitals NHS Foundation Trust at the London Cancer Children, Teenager and Young Adults Study Day, held on 25 July 2013.
SBIRT and SAMHSA's 8 Strategic Initiativessideponytail
Slides from a webinar held by the National SBIRT ATTC. Video is on TheIRETAChannel on Youtube: http://www.youtube.com/watch?v=f6NrKuGlGRs&feature=share&list=PLiML4AFpuB72LBaPShcu2yQv_WpsGY9a9
Aaron Brizell - ECO 17: Transforming care through digital healthInnovation Agency
Presentation by Aaron Brizell, Population Health Programme Manager, Wirral University Teaching Hospital NHS Foundation Trust: The benefits of system-wide population health and analytics at ECO 17: Transforming care through digital health on Tuesday 4 December at Lancaster University, Lancaster
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Reducing opioid prescribing, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Pharmacist Interventions and Medication Reviews at Care Homes - Improving Med...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Pharmacist Interventions and Medication Reviews at Care Homes - Improving Medication Safety and Patient Outcomes, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, SBAR Patient Engagement Tool, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Reducing medication related falls risk in patients with severe frailty, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Assessing the outcomes of structured medication reviews, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Polypharmacy SMR reviews in outpatient bone health clinics, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Polypharmacy reviews of asthma and COPD patients over 65 and 10 or more medic...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Polypharmacy reviews of asthma and COPD patients over 65 and 10 or more medicines, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Evaluating the impact of a specialist frailty multidisciplinary team pathway ...Health Innovation Wessex
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Evaluating the impact of a specialist frailty multidisciplinary team pathway with clinical pharmacist involvement, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Genome UK – State of the nation by Professor Dame Sue Hill, Chief Scientific Officer for England and NHS Genomics Programme Senior Responsible Officer.
Pharmacogenomics into practice - stroke services and a systems approach by Dr Richard Marigold, Consultant Stroke Physician and NIHR Hyperacute Stroke Research Centre Lead, University Hospital Southampton NHS Foundation Trust
To evaluate the benefits of Structured Medication Reviews in elderly Chinese ...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, To evaluate the benefits of Structured Medication Reviews in elderly Chinese patients, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary,
Review of patients on high dose opioids at Living Well PCN, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Re-establishing autonomy in elderly frail patients, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Improving Medication Reviews using the NO TEARS Tool, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Improving care in County Durham under the STOMP agenda - A 5 year review.pdfHealth Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Improving care in County Durham under the STOMP agenda - A 5 year review, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Impact of an EMIS search to prioritise care home residents for a pharmacist l...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Impact of an EMIS search to prioritise care home residents for a pharmacist led medication review, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Identifying Orthostatic Hypotension caused by Medication, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Wessex AHSN - Alcohol Related Liver Disease, Audit and Pathway
1. Background
• Admissions and deaths due to alcohol are increasing
• Liver deaths continue to rise while Mortality from
other conditions has been declining.
• Greatest increase in Liver deaths have been in
Alcohol Related Liver Disease
• Alcohol accounts for 77% of Liver Mortality
• 2010 BSG / BASL / Alcohol Health Alliance UK joint
position statement
2. NCEPOD 2013 National Confidential Enquiry into Patient Outcome and Death
Alcohol Liver Related Deaths
• Care `less than good `in more than half of cases reviewed
• Frequent Attenders – longer admissions – complex needs
• Missed opportunities during previous admissions
• RECOMMENDATIONS
• Screening of hospital patients for alcohol misuse/alcohol history
• Provide comprehensive physical and mental assessments, Brief
Interventions and access to specialist services within 24 hours of
admission
• The referral and outcomes should be documented in the notes and
communicated to the patient’s general practitioner
3. To improve health and
wellbeing of patients
presenting to hospital
with alcohol related liver
disease (ARLD)
AIM
4. OUTCOMES
• Reduce Emergency Admissions
• Reduce Bed days- length of stay
• Reduce Mortality
• Improve Patient journey
• Improve staff Knowledge
*Increased Rates of early detection of Harmful
Alcohol use and associated risk*
5. Audit sample
1. Patients 18 yrs who had a
Liver diagnosis and who
had a stay in Hospital of
over 24hrs FROM 01/01/15
– 31/03/15
2. K codes (liver disease)
6. Patient Journey
Admissions
• 67 % Admissions to MAU and AAU
Discharges
• 13% from MAU and AAU
• 36% from Gastro wards
• 7% from Coronary Care
• 12% from Surgery
• 12% other beds
• 20% Mortality
7. All Patients Admitted 1st Jan – 31st Mar 2015
Basingstoke and Winchester > 24 hrs
2
17
43
32
12
13
1
7
27
18
9 9
1
10
16
14
3
4
0
5
10
15
20
25
30
35
40
45
50
18-25 26-45 46-65 66-75 76-85 85+
All Patients
Male
Female
8. Length of Stay- All Admissions
36
41
29
12
8
4
0
5
10
15
20
25
30
35
40
45
1-2 days 3-7 days 8-14 days 2-4wks 1-2 mths 2 mth+
9. Length of Stay – ARLD Patients
10
15
13
6
3
1
0
2
4
6
8
10
12
14
16
1-2 days 3-7 days 8-14 days 2-4 wks 1-2 mths 2 mths+
10. ED attendances
<24 HRS STAY
• 220 ED attendances for Patient Group in
previous year
• 78 people attended on average 3 times each
during the period
• 10 most frequent attenders accounted for
44% of all of the A&E attendances.
• The most frequent attender visited ED 25
times in the period accounting for 11% of all
of the attendances
Continued
11. ED continued
• 12% (26) had a primary diagnosis of Alcoholic
liver disease
• Unspecified liver disease 5% (12)
• 55% (120 ) presentations resulted in Hospital
Admission
12. PATIENTS SCREENED
JANUARY – MARCH 2015
PATIENTS ADMITTED TO MAU –
BASINGSTOKE AND WINCHESTER
JANUARY 5% out of 1,234 patients
FEBRUARY 3% out of 1,148 patients
MARCH 3% out of 1,291 patients
Source - Business Intelligence and from Pastplus
Data -Alcohol Intervention Team
14. ARLD Admissions (39) NON ARLD Admissions (71)
87% Were asked about their
alcohol use
85.9% Were asked about their
alcohol use
(61)
38.4% Had units documented
(15)
11.4% Had units documented
1/3 Units incorrectly
calculated
Units correctly / incorrectly
calculated – unknown / not
documented
15. NON ARLD
61 PATIENTS ASKED ABOUT THEIR ALCOHOL INTAKE –
Documented:-
31
13
1
3
4
9
No alcohol intake =50.8%
Occasional =21%
Denied excess use = 1.6%
Audit C score – 1 positive (not
referred)=4.9%
Rarely / minimal = 6.5%
Alcohol Qty = 14.75%
16. Harm / Reduction Advice
1 person
Other
• 6 x Admitted HX excess alcohol use
• 5 x Conflicting accounts from Nursing /
Medics
• Documented not significant – elsewhere
documented >20 / 30 a week
• 1 x Elective admission, not on Endoscopy
admission
• 10 Patients not asked about their alcohol
use
17. ARLD – 33 PATIENTS
(39 Admissions)
3 ITU
34 Asked
2 Not asked
18. ARLD PATIENTS – 34 ASKED ALCOHOL HISTORY
DOCUMENTED:-
6
6
7
15
Stopped drinking / Not
current 17.6%
Quantities documented
17.6%
Vague History 20.5%
Unit History 44.1%
19. 34 Asked (above)
6 x Stopped drinking / Not current
6 x Quantities documented eg • Bottle of vodka a day
• 2 Glasses wine a day
• Bottle gin a day
• 2-3 bottles wine or ½ bottle vodka
• 300mls a day
• 3.5 litres cider
7 x Vague History eg • Couple whiskies a day
• Drinks one box
• High intake prior to fall
• Known to drink
• Multiple bottles of alcohol
15 x Unit History • 5 Incorrect
• 2 Conflicted
• 5 Correct
• 3 Not known
20. ISSUES IDENTIFIED
• Frequent attendances.
• Poor Alcohol History- vague
• Not Using Screening tool
• Risk of Withdrawal – longer admissions
• Lack of knowledge around units- reduced
confidence
• Limited referral to Specialist nurses
• More collaboration
• Specialist Liver nurse input
21. ALCOHOL RELATED LIVER DISEASE
INPATIENT PATHWAY
Questions
Scoring system Your
score0 1 2 3 4
How often do you have a drink
containing alcohol?
How many units of alcohol do you
drink on a typical day when you
are drinking?
How often have you had 6 or
more units if female or 8 or more
if male, on a single occasion in
the last year?
AVERAGE WEEKLY UNIT INTAKE – TOTAL...
ARLD DIAGNOSIS + POSITIVE ‘AUDIT
C’ AT INITIAL ASSESSMENT - SCORE
8+
ALCOHOL TEAMLIVER CONSULTANT
(A)
CARE BUNDLE IF DECOMPENSATED LIVER CIRROHIS
TRANSFER TO GASTRO WARD
(A)
DISCHARGE PLAN – INTERAGENCY CARE PLAN -
SUMMARY TO GP
MAU
1ST
24 HOURS
MANAGE AS PER POLICY IF THE RISK WITHDRAWAL
CIWA – PABRINEX – CONSIDER
ADJUNCTIVE PHARMALOGICAL THERAPY
ALCOHOL R/UHEPATOLOGY R/U (A)
WARD / MDT
(A)
HEPATOLOGY OPA
(A)
ALCOHOL FOLLOW UP
(A) =Auditable
PT LABEL
22. CHALLENGES
• Screening tool removed from Nursing Assessment
• Liver nurse not commissioned for ARLD
• Time lost – Non effective
• Screening for PH – Different procedure
• Limited In-Reach From Specialist services
• Not a 7 day week service
• Referrals
• Across two sites
23. NEXT STEP
• Training- Units awareness – staff MAU /AAU
• Screening
• B.I
• Referral !
• MDT attendance and Integrated Discharge
Planning
• Working Party
• Promote In –Reach
• OPA – With Gastro - Joint ARLD clinic
• Medical Training Re Documentation
24. Coding
Clinicians to be clear and detailed.
Harmful Use Code F101 – Not defined in ICD 10 ? Changes to Local
Hospital Policy for clear definition
Need a clear diagnosis documented - No ‘impressions’, no ‘queries’
and no ‘likely’.
Semantics –
Possible can not be coded – Probable is acceptable
Alcohol codes not documented unless:
Clearly written alcohol excess
• Secondary to alcohol
• Diagnosis is clear
• Units
• Advice given needs to be documented
25. On-going Service Development
• Co-ordination and Collaboration between interface of services
• Working party across both sites – to include Housing
Social services ,Mental Health ,Older Persons, Specialist services
• Pilot involvement with High Impact User Group – involving Police ,
Probation Mental Health , Ambulance
• Joint Assessment with Patients presenting with Mental Health
issues and Psychiatric Liaison
• Integrated pathways between hospital and community services-
• Identification of patients who can finish treatment with community
services
• Professionals Meeting prior to discharge to devise care plan at D/C
so can be on clinical tag if were to be readmitted either site
• Attendance at Gasto Ward MDT – enable early discharge planning
• Development of joint ARLD – Consultant / Alcohol Follow up